Alyeska Investment Group
DFTX

Alyeska Investment Group’s Definium Therapeutics DFTX Stock Holding History

Alyeska Investment Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66,694
Closed -$379K – 624
2024
Q3 		$379K Buy
+66,694
New +$464K ﹤0.01% 494
2023
Q3 		– Sell
-796,962
Closed -$2.85M – 578
2023
Q2 		$2.85M Sell
796,962
-245,677
-24% -$847K 0.02% 383
2023
Q1 		$3.31M Sell
1,042,639
-57,361
-5% -$191K 0.03% 326
2022
Q4 		$2.42M Buy
1,100,000
+100,000
+10% +$278K 0.03% 306
2022
Q3 		$3.5M Buy
+1,000,000
New +$9.6M 0.04% 288

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group's DFTX Position: Q4 2024 in Review

Alyeska Investment Group sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 66,694 shares — an estimated $379K sold.

Alyeska Investment Group first reported a position in DFTX in Q3 2022 and held it in 5 quarters. The position peaked at $3.5M in Q3 2022. 171 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • Alyeska Investment Group reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 66,694 Definium Therapeutics shares in Q4 2024, an estimated $379K.
  • Alyeska Investment Group first reported a position in Definium Therapeutics in Q3 2022 and held it in 5 quarters.
  • Alyeska Investment Group's Definium Therapeutics position peaked at $3.5M in Q3 2022.
  • 171 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on Alyeska Investment Group's 13F filing for Q4 2024, filed 14 Feb 2025.